GeneCentric Diagnostics

280 S. Mangum Street Suite 350
Durham, NC 27701
Click for website

Research Sector Diagnostics

Summary Description Developing assays for use in clinical laboratories for diagnosis in cancer treatments

Management Dr. Myla Lai-Goldman MD, CEO; Dr. David Neil Hayes, MD MPH MS; Dr. Mark R. Miglarese, PhD, Chief Scientific Officer; Dr. Charles M. Perou, PhD; Dr. Hawazin Faruki, Vice President for Clinical Development

Click here for Financial Data
Keywords: Cancer, Diagnostics, Lung Cancer, Anti-Angiogenesis Therapies, Oncology


Updated: May 07, 2017


Utilizes a unique partnership model to translate important cancer discoveries into clinically adopted diagnostics for pathologists, clinicians, and, most importantly, patients. By partnering with the ......view more

Products / Services

1. The Lung Subtype Platform (LSP): HistoPlusSM: Lung Cancer 2. Hypoxia Signature......view more

Technology / Differentiation

Founded based on intellectual property from Drs. Neil Hayes and Chuck Perous laboratories at the Lineberger Comprehensive Cancer Center at the UNC School of Medicine. Currently has two unique plat...view more

Market / Customers

The company partners with diagnostic and pharma companies; tests target pathologists and oncologists. Global in vitro diagnostic market estimated at $48B in 2012, and approximately $9.6B spent on l......view more

Competitors / Substitutes / Alternatives

LSP Competitors supply lung cancer diagnostics, including Allegro Diagnostics, Biodesix, BioView, and GE. Hypoxia Signature assay competitors have tests with prognostic potential for breast, lung, or...view more

Revenue / Funding

Funding to date: $5.25M - 12/2013 Financing sought: Completed Series A Funding in June 2013....view more